Literature DB >> 16737911

Molecular cytogenetic characterization of a metastatic lung sarcomatoid carcinoma: 9p23 neocentromere and 9p23-p24 amplification including JAK2 and JMJD2C.

Antoine Italiano1, Rita Attias, Alain Aurias, Gaëlle Pérot, Fanny Burel-Vandenbos, Josiane Otto, Nicolas Venissac, Florence Pedeutour.   

Abstract

Sarcomatoid carcinoma of the lung (LSC) is a rare lung cancer characterized by an admixture of carcinoma and sarcoma components. Data concerning the genomic alterations of LSC are almost nonexistent. Here, we report on the first molecular cytogenetic characterization of a metastatic LSC. Cytogenetic and multicolor fluorescence in situ hybridization (M-FISH) analyses showed a near-triploid karyotype with numerous structural aberrations and four to six small supernumerary marker chromosomes containing chromosome 9 sequences. Comparative genomic hybridization on arrays (array CGH) detected an amplification of 9p23 approximately p24.3 and gains of 1q11 approximately q23.3, 3q26.2 approximately q29, and 17q23.2 approximately q24.1. The 9p amplification was also detected in the primary tumor and another metastasis of the same patient, indicating it was a significant element in the pathogenesis of this LSC case. Complementary FISH analysis showed that the small supernumerary chromosomes were isochromosomes for 9p23 approximately p24.3. These isochromosomes were lacking alpha-satellite sequences although they were still stable after 55 passages in culture. As demonstrated by immunostaining with anti-centromere antibodies, they contained a functional centromere. So-called analphoid "neocentromeres" are rare and have been mainly described in constitutional abnormal karyotypes. This case is the third description of the identification of neocentromeres in cancer, (i.e. well-differentiated liposarcoma and acute myeloid leukemia), and is the first one in a carcinoma. Our results suggest that the 9p23 neocentromere of this case of LSC might be similar to a 9p23 neocentromere previously identified in two constitutional cases. The frequency of neocentromere formation in solid tumors may indeed be underestimated and may have a significant implication in chromosomal instability in tumor cells.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16737911     DOI: 10.1016/j.cancergencyto.2006.01.004

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  43 in total

Review 1.  Neocentromeres and epigenetically inherited features of centromeres.

Authors:  Laura S Burrack; Judith Berman
Journal:  Chromosome Res       Date:  2012-07       Impact factor: 5.239

Review 2.  Putting CENP-A in its place.

Authors:  Madison E Stellfox; Aaron O Bailey; Daniel R Foltz
Journal:  Cell Mol Life Sci       Date:  2012-06-23       Impact factor: 9.261

Review 3.  Neocentromeres: new insights into centromere structure, disease development, and karyotype evolution.

Authors:  Owen J Marshall; Anderly C Chueh; Lee H Wong; K H Andy Choo
Journal:  Am J Hum Genet       Date:  2008-02       Impact factor: 11.025

4.  Histone lysine demethylase (KDM) subfamily 4: structures, functions and therapeutic potential.

Authors:  Roselyne M Labbé; Andreana Holowatyj; Zeng-Quan Yang
Journal:  Am J Transl Res       Date:  2013-12-01       Impact factor: 4.060

5.  Histone demethylase GASC1, a potential prognostic and predictive marker in esophageal squamous cell carcinoma.

Authors:  Ling-Ling Sun; Andreana Holowatyj; Xiu-E Xu; Jian-Yi Wu; Zhi-Yong Wu; Jin-Hui Shen; Shao-Hong Wang; En-Min Li; Zeng-Quan Yang; Li-Yan Xu
Journal:  Am J Cancer Res       Date:  2013-11-01       Impact factor: 6.166

6.  Epigenetic dysregulation in cancer.

Authors:  Andrew G Muntean; Jay L Hess
Journal:  Am J Pathol       Date:  2009-08-28       Impact factor: 4.307

Review 7.  The role of histone demethylases in cancer therapy.

Authors:  Inga Hoffmann; Martin Roatsch; Martin L Schmitt; Luca Carlino; Martin Pippel; Wolfgang Sippl; Manfred Jung
Journal:  Mol Oncol       Date:  2012-08-07       Impact factor: 6.603

8.  Pro-growth role of the JMJD2C histone demethylase in HCT-116 colon cancer cells and identification of curcuminoids as JMJD2 inhibitors.

Authors:  Tae-Dong Kim; James R Fuchs; Eric Schwartz; Dalia Abdelhamid; Jonathan Etter; William L Berry; Chenglong Li; Michael A Ihnat; Pui-Kai Li; Ralf Janknecht
Journal:  Am J Transl Res       Date:  2014-05-15       Impact factor: 4.060

Review 9.  Histone lysine-specific methyltransferases and demethylases in carcinogenesis: new targets for cancer therapy and prevention.

Authors:  Xuejiao Tian; Saiyang Zhang; Hong-Min Liu; Yan-Bing Zhang; Christopher A Blair; Dan Mercola; Paolo Sassone-Corsi; Xiaolin Zi
Journal:  Curr Cancer Drug Targets       Date:  2013-06       Impact factor: 3.428

10.  Genomic amplification and oncogenic properties of the GASC1 histone demethylase gene in breast cancer.

Authors:  G Liu; A Bollig-Fischer; B Kreike; M J van de Vijver; J Abrams; S P Ethier; Z-Q Yang
Journal:  Oncogene       Date:  2009-09-28       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.